Lexicon Pharmaceuticals Inc
NASDAQ:LXRX

Watchlist Manager
Lexicon Pharmaceuticals Inc Logo
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Watchlist
Price: 1.1 USD -9.09% Market Closed
Market Cap: 399.5m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one LXRX stock under the Base Case scenario is 0.79 USD. Compared to the current market price of 1.1 USD, Lexicon Pharmaceuticals Inc is Overvalued by 29%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LXRX Relative Value
Base Case
0.79 USD
Overvaluation 29%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

12.8
P/S
P/S
Price to Sales
12.8
vs History
61
vs Industry
65
Median 3Y
109.2
Median 5Y
73.1
Industry
7.6
Forward
28.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-3
Industry
24.2
Forward
-2.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-3.4
Industry
20.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-3.1
Industry
22.9
More Details
3.2
P/B
P/B
Price to Book Value
3.2
vs History
39
vs Industry
62
Median 3Y
2.8
Median 5Y
3
Industry
2.9
More Details
8.4
EV/S
EV/S
Enterprise Value to Sales
8.4
vs History
61
vs Industry
9
Median 3Y
64.6
Median 5Y
54
Industry
7.9
Forward
18.7
More Details
8.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.6
vs History
57
vs Industry
6
Median 3Y
57.8
Median 5Y
41.8
Industry
10
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
33
Median 3Y
-2
Median 5Y
-2.4
Industry
5.1
Forward
-2.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
31
Median 3Y
-2
Median 5Y
-2.4
Industry
5.1
Forward
-1.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
34
Median 3Y
-2.1
Median 5Y
-2.6
Industry
5.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
30
Median 3Y
-2.1
Median 5Y
-2.6
Industry
4.2
More Details
2.9
EV/IC
EV/IC
Enterprise Value to IC
2.9
vs History
69
vs Industry
23
Median 3Y
5.9
Median 5Y
6.7
Industry
5.2
More Details

Multiples Across Competitors

LXRX Competitors Multiples
Lexicon Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
399.5m USD 12.8 -2.3 -1.5 -1.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 750 390.3 -160 410.6 -194 789.6 -192 566.9
US
Abbvie Inc
NYSE:ABBV
336.1B USD 5.9 80.9 15.4 22.7
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD 374 305.7 -13 141.6 -13 213.5 -13 207.5
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 4.8 27.8 14.8 24.4
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD 5 24.3 10.5 14.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD 10.9 -122 26 27.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.4 -532.6 -580 -564.5
AU
CSL Ltd
ASX:CSL
129.7B AUD 5.6 31 19 23.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD 4.3 13.5 12.1 13.6
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -66.5 -60
P/S Multiple
Revenue Growth P/S to Growth
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Average P/S: 3 102 441.2
12.8
5%
2.6
FR
Pharnext SCA
OTC:PNEXF
33 750 390.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
374 305.7
140%
2 673.6
US
Amgen Inc
NASDAQ:AMGN
4.8
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
5
3%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.9
10%
1.1
US
E
Epizyme Inc
F:EPE
2 087.4
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Average P/E: 35.5
Negative Multiple: -2.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 410.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.9
88%
0.9
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 141.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
27.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
24.3
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -122 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.6 N/A N/A
AU
CSL Ltd
ASX:CSL
31
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Average EV/EBITDA: 16.3
Negative Multiple: -1.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 789.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580 N/A N/A
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Average EV/EBIT: 21
Negative Multiple: -1.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 566.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.4
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.5
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.5 N/A N/A
AU
CSL Ltd
ASX:CSL
23.7
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60 N/A N/A

See Also

Summary
LXRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LXRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LXRX stock valuation using valuation multiples.
Wall Street Estimates
LXRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LXRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 270,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.